Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12550633 | 0.98 | PAOX (0.40) | PAOXHRH3KMT2AMEN1HPGD | |
| SCHEMBL12550634 | 0.98 | PAOX (0.40) | PAOXHRH3KMT2AMEN1HPGD | |
| SCHEMBL12550637 | 0.98 | PAOX (0.40) | PAOXHRH3KMT2AMEN1HPGD | |
| SCHEMBL1097459 | 0.93 | KMT2A (0.36) | PAOXHRH3KMT2AMEN1HPGD | |
| SCHEMBL898008 | 0.84 | ALDH1A1 (0.43) | KMT2AMEN1CYP1A2ALDH1A1CYP2C19 | |
| Hydrochloric Acid SCHEMBL5889035 | 0.82 | ALDH1A1 (0.41) | KMT2AMEN1CYP1A2ALDH1A1CYP2C19 | |
| SCHEMBL11269259 | 0.78 | KEAP1 (0.43) | HRH3KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12550619 | 0.78 | GNAO1 (0.48) | KMT2AMEN1CNR2 | |
| SCHEMBL5564599 | 0.78 | HRH3 (0.36) | PAOXHRH3KMT2AMEN1HPGD | |
| SCHEMBL11483699 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4001888-B1 | BIOLOGICAL TISSUE STAINING REAGENT, BIOLOGICAL TISSUE STAINING KIT AND BIOLOGICAL TISSUE STAINING METHOD | CUBICSTARS INC (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20220326125-A1 | BIOLOGICAL TISSUE STAINING REAGENT, BIOLOGICAL TISSUE STAINING KIT AND BIOLOGICAL TISSUE STAINING METHOD | CUBICSTARS, INC. (JP) | 2022-10-13 | — | — | US | disclosed |
| EP-4001888-A1 | BIOLOGICAL TISSUE STAINING REAGENT, BIOLOGICAL TISSUE STAINING KIT AND BIOLOGICAL TISSUE STAINING METHOD | Cubicstars, Inc. (JP) | 2022-05-25 | — | — | EP | disclosed |
| EP-2670765-B1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| CN-103429607-B | There is the triterpenoid that C-17 and C-3 of HIV maturation inhibit activities is modified | BRISTOL-MYERS SQUIBB CO. (US) | 2016-02-17 | — | — | CN | disclosed |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-8846647-B2 | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8828641-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8828641-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8268990-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| WO-2012106190-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20110129777-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-20110129777-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2222648-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | AstraZeneca AB (SE) | 2010-09-01 | — | — | EP | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | disclosed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | PAOX 4654/4885HRH3 1528/4885KMT2A 755/4885 |
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | PAOX 3737/4885HRH3 312/4885KMT2A 3784/4885 |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | PAOX 4337/4885HRH3 4483/4885KMT2A 4371/4885 |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | PAOX 4337/4885HRH3 4483/4885KMT2A 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.